METAP2 and obesity due to melanocortin 4 receptor deficiency: By integrating structural, mechanistic, and pharmacological insights, this review aims to pave the way for the rational design of next-generation MetAP2 inhibitors, offering new hope for effective and safe treatments for obesity and T2DM.